VCYT
BuyPremium GrowerAI neutralVeracyte, Inc. · Healthcare · United States · $3.9B cap · $69.5M/day traded
$50.31 +0.1% · close 28 Oct · scored 29 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Report expected 3 Nov: the next-year EPS estimate has risen 3.0% over the last 14 weeks.
As of 29 Oct 2026, MoatMap's StockRank for Veracyte, Inc. (VCYT) is 76/100, ranked against 24,000+ stocks in 35 markets (Quality 77, Value 34, Momentum 61, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Veracyte sells genomic diagnostic tests. Its Decipher prostate test is building a strong evidence base, including a Phase III trial showing it predicts which patients benefit from adding hormone therapy to radiation. It is also expanding in urology through the Convergent Genomics urine test. Growth and cash generation are real, but the valuation is not cheap and none of the macro themes drives the business, so the payoff depends on reimbursement and adoption rather than a clear mispricing.
ABOUT VERACYTE, INC.
Read
Veracyte, Inc. is a global diagnostics company focused on genomic tests for difficult-to-diagnose diseases, particularly in oncology, pulmonology, and endocrinology. Its competitive moat lies in its proprietary genomic platforms and clinically validated tests that provide actionable insights, reducing the need for invasive procedures. Veracyte is a specialized diagnostics leader, benefiting from strong intellectual property and a growing portfolio of revenue-generating precision medicine tests.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 296.5M | 361.1M | 445.8M | 517.1M | 20.4% | 561.9M | 593.6M | 659.7M | 12.9% |
| EPS | -0.51 | -1.02 | 0.32 | 0.84 | 162.5% | 1.40 | 0.90 | 0.92 | 4.5% |
| Shares | 72.0M | 73.3M | 77.8M | 79.4M | +10.3% | 80.4M | — | — | — |
| Debt | 14.7M | 12.6M | 50.7M | 39.7M | 39.1% | 40.1M | — | — | — |
| Equity | 1.1B | 1.0B | 1.2B | 1.3B | 6.8% | — | — | — | — |
| Op CF | 7.5M | 44.2M | 75.1M | 136.3M | 162.5% | 178.4M | — | — | — |
| Inv CF | -29.4M | 15.1M | -56.3M | -9.2M | — | — | — | — | — |
| Fin CF | 3.5M | 2.8M | 4.9M | -4.2M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 79% of stocks we rank over the past year (65% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VCYT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VCYT | Veracyte, Inc.(you) | $3.9B | 76 | Buy |
| SHC | Sotera Health Company | $5.2B | 79 | Buy |
| CDNA | CareDx, Inc. | $3.6B | 62 | Hold |
| BLLN | BillionToOne, Inc. | $5.1B | 57 | Hold |
| ADPT | Adaptive Biotechnologies Corporation | $4.1B | 47 | Hold |
| GRAL | GRAIL, Inc. | $5.9B | 50 | Hold |
| NEO | NeoGenomics, Inc. | $2.1B | 49 | Hold |
| RVTY | Revvity, Inc. | $17.7B | 65 | Buy |
| RDNT | RadNet, Inc. | $5.5B | 40 | Hold |
| CRL | Charles River Laboratories International, Inc. | $16.6B | 62 | Hold |
Peer medians: ROE -30.5% · P/E 27.2x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.